Novo Nordisk's provocative campaign in Madrid aims to destigmatize obesity by declaring it a disease, not an aesthetic issue. Despite its support from obesity advocacy groups, the campaign has drawn criticism for being offensive and commercial. Users have accused Novo Nordisk of exploiting the topic for profit, particularly given their connection to the anti-obesity drug Ozempic. The campaign includes a video where a contestant acknowledges the challenges of obesity, yet this too has been labeled fatphobic. This initiative reignited discussions about the societal perception of obesity and the language used to address it.
This campaign highlights obesity as a serious health issue, yet it has faced backlash for being insensitive and overly commercialized by Novo Nordisk.
A recent campaign by Novo Nordisk has sparked fierce debate about obesity, leading to accusations of insensitivity and exploiting a serious health issue for commercial gain.
Collection
[
|
...
]